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Abstract 
We conducted a performance assessment study for a new sustained-release 
capsule including starch-sponge matrix (SSM). The SSM, which is a support 
medium for drug release, was made from 2.5% cornstarch glue by means of 
freezing dry method. The SSM capsule was applied for nifedipine (NFP), a 
calcium channel blocker, and evaluated pharmacokinetic and 
pharmacodynamic (PK/PD) profiles of NFP after intraduodenal 
administration of SSM capsules including 2.5 or 5.0 mg of NFP per capsule 
to rats. Plasma NFP concentrations from the SSM capsules showed dose-
dependent increases with a Michaelis-Menten like behavior over 360 minutes 
after intraduodenal administration. The values of area under the 
concentration vs. time curve from time zero to 360 min (AUC0-360) of NFP 
declined in making SSM capsules as compared to control capsules due to a 
simple physical mixture of NFP and cornstarch, but the values of mean 
residence time (MRT0-360) extended and abidingness of SSM capsules were 
admitted with dose-dependent manner. As for a PD parameter, the mean 
arterial blood pressure (mABP) derived from the SSM capsules showed 
15~20% decrease of baseline within 120min after intraduodenal 
administration, and thereafter the mABP in 2.5 mg SSM capsule was 
gradually recovered, while a relatively smooth and even change was found in 
the mABP at 5.0 mg SSM capsule. The relationships between plasma NFP 
concentration and sampling-time corresponding mABP after intraduodenal 
administration of SSM capsules showed no rapid change in the mABP, 
indicating that a sustained-release mechanism due to the SSM functions 
sufficiently to avoid a fluctuating blood pressure accompanied by going up 
and down of plasma levels of NFP. The SSM capsules exhibited a sustained-
release pharmacokinetics of NFP, and made the fluctuation range with blood 
pressure small compared to the physical mixture preparations. Thus, it was 
evidenced that the SSM capsule is useful device to provide a sustained-
release systems and optimal therapeutic efficacy of drugs.  
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Introduction 
In the field of manufacturing medicine, there are 
a numerous number of reports regarding 
sustained-release systems of drugs, where 
various types of pharmaceutical additive are 
used for making. The sustained-release systems 
of drugs provide several advantages for drug 
therapy, for instance, increasing in patients’ 
compliance, avoiding side effects and 
prolongation in efficacy periods, and so on. 
Cornstarch is generally used as a pharmaceutical 
excipient to prepare tablets or capsules. 
Moreover, natural starches and chemical 
modified starches such as substituted amylase 
[1], cross-linked amylase [2], starch acetate [3] 
or amylodextrin [4] have been extensively 
investigated as sustainedrelease excipients for 
tablets by direct compression. Thermally 
pregelatinaized starches also proved to be 
suitable for formulating hydrophilicmatrices [5–
7]. In our previous report, we developed a new 
sustained-release system using cornstarch glue, 
namely, a capsule including starch-sponge 
matrix (SSM). The SSM capsule is composed of 
a gelatin capsule and SSM with drug, and the 
SSM has a porous and netlike structure with 
Krumbein’s diameter of 5～22 µm, and has 
mucoadhesive property to increase absorption 
rate of a drug at intestinal tract [8]. The SSM 
capsule, therefore, could be applied for various 
types of drugs with various lipophilicity [8]. 
This time, we conducted a performance 
assessment study for this new sustained-release 
capsule including the SSM. This SSM capsule 
was applied for nifedipine (NFP), a calcium 
channel blocker, and evaluated pharmacokinetic 
and pharmacodynamic (PK/PD) profiles of NFP 
after intraduodenal administration of the SSM 
capsules including 2.5 or 5.0 mg of NFP per 
capsule in rats. NFP was dispersed in paste-like 
cornstarch (starch glue) after heating 2.5% (w/v) 
cornstarch suspension with electromagnetic 
wave at 2450 MHz (700 W) for l min. Then the 
drug mixture was encapsulated into a five 
number gratin capsule by a syringe, and the 
SSM capsule including NFP was prepared by 
means of a freezing dry method. In this study, 
the mean arterial blood pressure (mABP) was 
used as an indicator for the pharmacodynamic 
parameter. 
 
Materials and methods 
Chemicals and stock solutions 
Cornstarch to make a sustained-released matrix 
in capsule, NFP (LogPow=3.23) and midazolam 
(MDZ, an internal standard for drug assay) were 
purchased from Nacalai Tesque, (Kyoto, Japan). 
A five number gelatin capsule (4 mmφ×10 mm, 
volume 150 µL), Japanese Pharmacopoeia 
grade, was purchased from Matsuya Co. Ltd. 
(Osaka Japan). All other chemicals and reagents 
were used of analytical grade without further 
purification. MDZ solution used drug assay was 
prepared by dissolving MDZ in methanol to a 
final concentration of 1 µg/mL.  
 
Animals  
Male Wistar rats of 300 to 350 g were procured 
from Nippon SLC Co. Ltd. (Hamamatsu, 
Japan). All animal experiments were performed 
in accordance with the guidelines for animal 
experimentation of Doshisha Women’s College 
of Liberal Arts, Pharmaceutical Division and 
federal requirements for animal studies. Rats 
have free access to food and water and were 
housed in temperature control facility (22±2°C) 
with a 12-hour light/dark cycle for at least one 
week before use.  
 
Preparation of SSM capsules of NFP  
Preparation method for SSM capsule of NFP 
was previously described.[8] In brief, cornstarch 
was suspended in distilled water at a final 
concentration of 2.5% (w/v), then the mixture 
was microwaved at 2450 MHz (700 W) for 1 
min to make starch glue. After cooling the glue 
in a ice bath, NFP was added and mixed well in 
a mortar. The final concentrations of NFP in 
starch glue were 16.7 or 33.3 mg/mL. After 
making a 300 µm i.d. hole with a micro-drill in 
the middle portion of a five number gelatin 
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capsule at the junction of cap and body, 150 µL 
aliquot of drug mixture with glue loaded by a 
syringe, then immediately the mixture loaded 
capsule was frozen at －80°C in a deep freezer. 
Then a freeze-dried method (－50°C, 9.9 Pa, for 
24 hr) was applied for these preparations to 
make SSM capsule including 2.5 or 5 mg of 
NFP per capsule. As control formulations for 
NFP, physical mixture (PM) between NFP and 
cornstarch was prepared at a final concentration 
of 16.7%(w/w), and this diluted drug powder 
was encapsulated to the number five gelatin 
capsule at 2.5 or 5 mg/capsule, where the 
amount of cornstarch used to prepare capsules 
was the same between SSM capsules and PM 
capsules as control.  
 
Animal operation and monitoring of blood 
pressure  
After over night fasted though water allowed ad 
libitum for 16-18 hours prior to experiment, rats 
were anesthetized by intraperitoneal 
administration of urethane (1.0 g/kg) and placed 
in supine position on surgical table under an 
incandescent lamp to keep body temperature at 
37°C. The carotid artery was cannulated with 
poly-ethylene tubing (i.d. 0.5 mm, o.d. 0.8 mm) 
containing heparinized saline (100 IU/ml) for 
measurement of blood pressure. A small 
longitudinal section was made in the skin of the 
rat over the left jugular vein for the collection of 
blood samples over time. The carotid artery was 
attached to blood pressure monitoring kit 
(Nihon Kohden, Japan) through the carotid 
artery cannula. The systolic and diastolic blood 
pressure were measured by using the Notocard 
HEM data acquisition and analysis system 
(Notocard HEM 3.5, France), and the output 
was continuously displayed on digital screen 
attached to the system.  
 
Drug administration and sample collection  
Rats received intraduodenal administration of 
control or SSM capsules including NFP (2.5 mg 
or 5 mg). After making a small incision on 
duodenal wall at the position of just passing 
over the biliary duct, a capsule was inserted. 
Then the wound site was made three stitches by 
suture thread and pasted by surgical glue. Blood 
samples of 120 µL each were collected into a 
1.5 mL heparinized polyethylene centrifuging 
tube from the right jugular vein at 10, 20, 30, 
60, 90, 120, 180, 240 and 360 min. The blank 
blood samples were taken at 5 min prior to the 
intraduodenal administration of capsule. The 
blood samples were centrifuged at 3000×g for 
15 min at 4°C, and 50 µL of plasma was 
obtained, and then stored at －20°C until 
analysis.  
 
Assay for NFP 
NFP in plasma was extracted by taking 50 µL of 
aliquot of plasma into a polyethylene centrifuge 
tubes and 2.5 mL of MDZ solution 
(0.0025ng/mL) was added as an internal 
standard and mixed for 30 s, then 100 µL of 2% 
(w/v) ZnSO4 in 50% (v/v) methanol solution 
was added to precipitate proteins. The mixture 
was mixed for 30 s and centrifuged at 3000×g 
for 15 min. The clear supernatant was 
transferred into a 1.5 mL polyethylene 
centrifuge tubes and 1 mL of diethyl ether was 
added, then the mixture was mixed for 30 s and 
centrifuged at 3000× g for 15 min. Decant the 
supernatant into a new glass test tube and 
evaporate in an evaporator for 30 min at 45°C. 
The residue was then reconstituted in 1 mL of 
HPLC mobile phase and 20 µL was injected 
into liquid chromatography-tandem mass 
spectrometer (LC/MS/MS) system. The 
LC/MS/MS (Sciex, 4000 Q TRAP with 
Analyst1.4.1 version) analysis was carried out 
by equipping with an HPLC system (Shimadzu, 
Kyoto, Japan). The mobile phase which consists 
of 90% (v/v) acetonitrile containing 0.1% 
formic acid was degassed before use. The 
sample elution was performed with a flow rate 
of 0.2 mL/min, and each analysis lasted for 5.0 
min. The mass spectrometer was operated in the 
turbo-ion spray mode with positive ion 
detection. The flow rate of nebulizer gas, curtain 
gas and collision gas were set at 8, 8 and 
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2L/min, respectively, and the ion spray voltage 
and temperature were set at 5000 V and 300°C. 
The declustering potential, the focusing 
potential, the entrance potential, the collusion 
energy and the collision cell exit potential were 
set at 20, 200, -10, 30 and 6 V, respectively. 
Multiple reactions monitoring analysis was 
performed with the transition m/z 296 for NFP 
and m/z 326 for MDZ. All raw data were 
processed with Analyst Software, version 1.4.1. 
Taking the peak area ratio of NFP against the 
internal standard (MDZ), the calibration curves 
of NFP were made in plasma. The retention 
times for NFP and MDZ were 2.24 and 1.78 
min, respectively. Calibration curve of NFP 
were linear and passed through the origin with 
correlation coefficients of 0.999 or over. The 
limits of detection were NFP was 0.005 µg/mL.  
 
Pharmacokinetic (PK) and pharmacodynamic 
(PD) analysis  
PK parameters from each of the individual rats 
plasma concentration–time profiles of NFP were 
analyzed by non-compartmental method. The 
area under the plasma concentration–time curve 
from time 0 to the last time (AUC0-360) was 
calculated by using a linier trapezoidal rule. The 
area under the first moment curve to the last 
measurable concentration (AUMC0-360) was also 
calculated by a linier trapezoidal rule, and the 
mean residence time to the last measurable 
concentration (MRT0-360) was calculated by an 
equation of AUMC0-360/AUC0-360. Then, the 
variance of MRT0-360 (VRT0-360) was calculated. 
As for PD parameters, the mean arterial blood 
pressure (mABP) was calculated every 5 
minutes using continues record of systolic and 
diastolic blood pressure before and after 
intraduodenal administration of the SSM or 
control capsules using full excerpts of diastolic 
or systolic arterial blood pressure from 
continuous Notocord HEM 3.5 records and 
noted mean values corresponding at 0, 10, 20, 
30, 60, 90, 120, 180, 240 and 360 min after 
intraduodenal administration of NFP capsules. 
 
Statistical analysis 
Values are expressed as their mean or 
mean±SD. Statistical significance for the mean 
values was accepted when the p-value was less 
than 0.05, using a one-way analysis of variance 
and a multiple comparison test. 
 
Results 
Absorption efficacy of NFP from the SSM 
capsule after intraduodenal administration was 
studied in rats. Figure 1 shows the plasma NFP 
concentration vs. time curves after 
administration of 2.5 mg/capsule or 5.0 
mg/capsule with or without the SSM. After 
administration of PM capsules, plasma NFP 
concentrations showed dose-dependent 
increases with maximum concentrations around 
180 min, and thereafter decreased gradually. 
 
Table 1 Pharmacokinetic parameters of NFP after intraduodenal administration of SSM capsules by non-compartmental 
method. 
 
NFP 2.5 mg/capsule                  NFP 5.0 mg/capsule 
 
Controla)   SSM    Controla)     SSM 
 
 
AUC0-360   3180±890   1115±221   5790±1765   2387±239 
(µg・min/mL) 
 
 
 
MRT0-360    205±10                  233±21                    208±8                   219±11 
(min) 
 
 
 
VRT0-360                     222267±36674           555612±29173**             119779±45097                  273036±72764** 
(min2) 
 
Values are expressed as mean ± SD; n= 6 in each group. **): p<0.01 against respective control. a) Control capsules were 
prepared by mixing NFP with cornstarch (physical mixture). 
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Fig. 1: Plasma NFP concentration-time curve after 
intraduodenal administration of SSM capsules of NFP to 
rats. 
 
Each value represents the mean±SD of 6 rats in each 
group. 
 
Key: Δ, PM capsule (2.5 mg/rat); ▲, SSM capsule (2.5 
mg/rat); ○, PM capsule (5.0 mg/rat); ●, SSM capsule (5.0 
mg/rat) 
 
On the other hand, after administration of SSM 
capsules, its plasma NFP concentrations showed 
dose-dependent and Michaelis-Menten like 
increases without peak concentrations over 360 
minutes. PK parameter values, which were 
calculated using the non-compartmental analysis 
method, are listed in Table 1. The AUC0-360 
values for NFP with PM capsules including 2.5 
mg or 5.0 mg NFP were 3180±890 or 
5790±1765 µg・ min/mL, respectively, whereas 
those for NFP capsules with SSM were 
1115±221 or 2387±239 µg・min/mL, 
respectively. On the other hand, the MRT0-360 
vales for NFP capsules with PM including 2.5 
mg or 5.0 mg NFP were 205±10 or 208±8 min, 
respectively, whereas those for NFP capsules 
with SSM were 233±21 or 219±11 min, 
respectively. The VRT0-360, which values are 
related to the effectiveness of capsules, for NFP 
capsules with PM including 2.5 mg or 5.0 mg 
NFP were 222267±36674 or 119779±45097 
min2, respectively, while those for NFP capsules 
with SSM were 555612±29173 or 
273036±72764 min2, respectively. 
 
As for PD parameter, we used the mean arterial 
blood pressure (mABP). Figure 2 shows 
changes in mABP after intraduodenal 
administration of NFP capsules. The data show 
percent changes of mABP in rats. After 
intraduodenal administration of NFP capsules 
without SSM in rats, consecutive decrease in the 
relationship between mABP and time, and 5 mg 
capsule without SSM showed a profound effect 
to reach at 40% decrease of baseline during 180 
to 360 min. On the other hand, after 
intraduodenal administration of NFP capsules 
with SSM, the mABP of both capsules, 
including 2.5 mg or 5.0 mg NFP, showed 
15~20% decrease of baseline within 120min. 
Thereafter, the mABP in 2.5 mg SSM capsule 
was recovered gradually, while a relatively 
smooth and even change was found in 5.0 mg 
SSM capsule.  
 
 
Fig. 2: Mean arterial blood pressure (mABP)-time curve 
after intraduodenal administration of SSM capsules of 
NFP to rats. 
 
Each value represents the mean of 6 rats in each group. 
 
Key: Δ, PM capsule (2.5 mg/rat); ▲, SSM capsule (2.5 
mg/rat); ○, PM capsule (5.0 mg/rat); ●, SSM capsule (5.0 
mg/rat) 
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Fig.3: Relationship between plasma NFP concentration and mean blood pressure after intraduodenal administration of SSM 
capsules of NFP to rats. Rats received 2.5 mg NFP (a) or 5.0 mg NFP (b) by PM capsule or SSM capsule. Arrowed lines 
represent proceeding with time from zero to 360 min. Each value represents the mean±SD of 6 rats in each group. Key: ○, 
PM capsule; ●, SSM capsule. 
 
To evaluate the relationship between plasma 
NFP concentration and mABP, the values of 
mABP corresponding to sampling times were 
calculated using full excerpts from continuous 
Notocord HEM 3.5 records. Figure 3 represents 
the relationships between plasma NFP 
concentration and the sampling-time 
corresponding mABP. In the PM capsules, even 
if NFP concentration in plasma passed the peak 
level, the mABP continued to fall. However, in 
case of the SSM capsules, a rapid change was 
not found in the values of mABP, indicating that 
a sustained-release of NFP from the SSM 
functions sufficiently. 
 
Discussion 
Oral delivery of drugs is the most attractive 
route of administration, where sustained release 
system is one of major field in pharmaceutics to 
provide reasonable therapeutic effects of drug as 
well as to increase the patient’s conveniences 
[9]. There are a large number of reports about 
sustained-release drug delivery system to 
increase oral bioavailability using excipients 
beside   of   starches,   therapeutic   effect   and  
 
duration of action of drugs. Solid dispersion 
systems using polyvinilpirolidone[10], 
polyethylenglycol [11] or fine porous silica 
particles [12,13] are useful method to improve 
drug release and solubility. Moreover, the 
hydrophilic nanoparticles or microspheres using 
polymers such as chitosan or poly(D,L-lactic-
co-glyceric acid) have received much attention 
to deliver therapeutic peptide, protein, antigen, 
oligonucleotide and gene by intravenous, oral or 
mucosal administration [14,15]. In addition, 
nanoparticles or microspheres using such 
biodegradable pharmaceutical products have a 
mucoadhesive property to increase drug 
bioavailability [17-18]. Recently, we developed 
a new sustained-release system for therapeutic 
drugs using starch glue, namely, a starch-sponge 
matrix (SSM) sustained capsule [8]. The SSM 
capsule we developed was made from one of 
natural starches, corn starch, and the SSM had a 
matrix structure to regulate the drug release in 
vitro and in vivo [8]. The SSM capsule based on 
starch glue provided sustained release following 
Higuchi’s diffusion controlled model [19], 
because the SSM had a ghost matrix after drug 
release in vitro. Moreover, it was found by X-
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ray contrast examination that the SSM has local-
residential and mucoadhesive properties. This 
mucoadhesive property is an important 
characteristic for the sustained-release system to 
maintain a constant plasma drug levels [20-22]. 
In this study, as a next step, we evaluated the 
PK/PD aspects of the SSM capsule for NFP.  
 
NFP, a hypertensive calcium channel blocker, is 
commonly administered to subjects with 
coronary heart disease who often exhibited 
hyperlipidemia or diabetics mellitus [23]. In the 
current study, doses of 2.5 mg/rat and 5.0 mg/rat 
were used to examine the usefulness of the SSM 
capsule. However, therapeutic dose of oral NFP 
is <1 mg/kg in human patients [24]. If assuming 
that rat’s body weight was 300 grams, the 
applied-doses of NFP in this study were 8.3 
mg/kg and 16.7 mg/kg, respectively, and those 
were apparently over-dose.  
 
As NFP is more stronger in the affinity to the 
peripheral-vessel than in the heart, an overdose 
of NFP causes a reflectivity pulsus frequens due 
to blood pressure fall as a result of restraining 
Ca2+ entry to the vascular smooth muscle [25]. 
In deed, the heart rate in rats after 
intraduodenum administration of SSM capsule 
of NFP increased (data not shown). In this 
study, however, we focused to investigate about 
pharmaceutical property of NFP capsule with 
SSM. As shown in Figs 2 and 3, a sustained-
release aspects were brought and the fluctuation 
range with blood pressure became small in the 
SSM capsules as compared to the capsules of 
physical mixture between NFP and cornstarch. 
The values of AUC0-360 for NFP declined in 
making SSM capsules, but the values of MRT0-
360 extended and abidingness of SSM capsules 
was admitted, and moreover they were dose-
dependent. Thus, it was evidenced that the SSM 
capsule is useful device to provide a sustained 
release systems and optimal therapeutic efficacy 
of drugs.  
 
Essentially, drug-free SSM has a porous and 
netlike structure, and the distribution aspect of 
model drugs in the SSM depends on 
physicochemical properties between cornstarch 
glue and drugs. In our previous report, three 
representative drugs (uranine, indomethacin and 
nifedipine) with different physicochemical 
properties were selected as model drugs and in 
vitro release and in vivo pharmacokinetics were 
examined [8]. Uranine with much lower 
lipophilicity exists in continued phase of SSM, 
and indomethacin or NFP with a moderate or a 
higher lipophilicity exist in continues phase or 
porous space of the SSM. In the in vitro 
dissolution study, the release rate of drug from 
the SSM was mainly dependent on the 
lipophilicities of drugs, showing a rank order of 
the release rate as uranine > indomethacin > 
NFP. Moreover, the sustained-release effect of 
SSM capsule was enhanced with an increase in 
the lipophilicity of a drug, and local-residential 
and mucoadhesive properties of SSM in the 
intestine provided stable supply of drugs from 
the SSM. Moreover, the in vitro release rate for 
each drug was well regulated by changing the 
initial concentration of cornstarch suspension. In 
addition, in vivo absorption studies in rats, after 
intraduodenal administration of SSM capsules 
including those model drugs revealed that the 
sustained-release effects also could be regulated 
by the initial concentration of starch suspension. 
As evaluated here, the SSM capsules for NFP 
showed a sustained-release profiles of NFP and 
the small fluctuation in blood pressure as 
compared to the control capsules, suggesting 
that the SSM capsules can contribute to avoid 
abrupt increase or drastic decline in plasma NFP 
levels and side effects which are related to 
fluctuation of cardiovascular parameters. The 
SSM capsule we developed, therefore, shows 
promising results as an oral drug delivery 
system for sustained-release regulation or target 
specificity in the lumen. 
 
Conclusion 
A new sustained-release capsule using the SSM 
derived from cornstarch glue was applied for 
NFP, and its PK/PD aspects in rats were 
evaluated. The SSM capsule exhibited a 
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sustained-release pharmacokinetics of NFP, and 
made the fluctuation range with blood pressure 
small as compared to the capsule of physical 
mixture. The SSM capsule is useful device to 
provide a sustained-release systems and optimal 
therapeutic efficacy of drugs. 
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